AED bone/cartilage composition and reported knee-osteoarthritis comparison — RU2299741C1
Patent disclosure · 2007
- What the patent describes
- 29 knee-osteoarthritis patients ages 52–72; the patent states random allocation and describes 12 saline controls. Treatment subgroups differed by age, disease severity and dose.
- Reported evidence
- The patent reports pain reduction and better mobility in 54.5–62.7% of cases across severity subgroups after 20 days of intramuscular AED, without substantial radiographic change. Control response and subgroup counts are not supplied. It also contains separate animal and cartilage-explant examples.
Reported patent results
Reported findings
The patent reports less pain and better knee mobility after 20 days of intramuscular AED. It reports no substantial X-ray change.
29 knee-osteoarthritis patients ages 52–72; the patent states random allocation and describes 12 saline controls. Treatment subgroups differed by age, disease severity and dose.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain and joint mobility | Improvement reported in 54.5–62.7% of cases | Range across disease-severity subgroups; subgroup counts and control response are not reported · 20-day course |
| X-ray findings | No substantial radiographic change | During the reported treatment period |
| Patient population | 29 patients ages 52–72; 12 saline controls described | Disease duration 5–20 years |
| Age 52–60, initial disease | 1 microgram intramuscularly once daily | 20 days |
| Age 60–65, moderate deformity | 10 micrograms intramuscularly once daily | 20 days |
| Over 65, most marked deformity | 5 mg intramuscularly once daily | Source units retained; severity-dependent groups are not a dose-response trial · 20 days |
These are patent-reported human observations, not a peer-reviewed clinical trial. The percentages describe reported symptom responses, not the amount of cartilage restored or a treatment-versus-control effect.
Source for these results ↗ · Reviewed 2026-10-31
Patent claims and provenance
Molecule. The claim explicitly identifies Ala-Glu-Asp (AED), with bone/cartilage applications; this is not the cartilage-derived PCC mixture.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2299741C1 ↗ · 2007-05-27
- Earliest priority / filing
- 2006-05-30 / 2006-05-30
- Original applicant / assignee
- Общество С Ограниченной Ответственностью "Сиа Пептайдс"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 38310627 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using
Inventors: Владимир Хацкелевич Хавинсон (RU); Владимир Хацкелевич Хавинсон; Евгений Иосифович Григорьев (RU); Евгений Иосифович Григорьев; Владимир Викторович Малинин (RU); Владимир Викторович Малинин; Галина Анатольевна Рыжак (RU); Галина Анатольевна Рыжак.
Study limitations and source details
Study limitations
- Patent-reported comparison, not a recovered peer-reviewed clinical trial.
- Allocation methods, masking, subgroup denominators and independent replication remain unresolved.
- This AED example is not the PCC Phase II program reported in 2023.
Source details
Original patent text and translated examples checked; filed 2006, published 2007. Clinical example 5 rechecked on 31 October 2026, including doses, symptom-response range and absent radiographic change.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
V. Kh. Khavinson, E. I. Grigoriev, V. V. Malinin, G. A. Ryzhak. AED bone/cartilage composition and reported knee-osteoarthritis comparison — RU2299741C1 Russian patent RU2299741C1; related Eurasian patent EA010574